Embody raised US $1.5MM to support development of a biologic treatment for Achilles tendon and ligament injuries. The collagen-based nanofiber grafts, formed with electrospinning and microfluidic fabrication techniques, are resorbable and designed to mimic the architecture of the native tendon.
The company is pursuing FDA clearance and intends to launch product in 2019.
This funding was led by 757 Angels and the Center for Innovative Technology, and builds upon the nearly $13.0MM previously raised by the company in a combination of an economic development loan ($0.15MM), state-based research grant ($0.8MM) and a DARPA grant to advance treatment of service members and veterans ($12.0MM).
Embody raised US $1.5MM to support development of a biologic treatment for Achilles tendon and ligament injuries. The collagen-based nanofiber grafts, formed with electrospinning and microfluidic fabrication techniques, are resorbable and designed to mimic the architecture of the native tendon.
The company is pursuing FDA clearance and intends...
Embody raised US $1.5MM to support development of a biologic treatment for Achilles tendon and ligament injuries. The collagen-based nanofiber grafts, formed with electrospinning and microfluidic fabrication techniques, are resorbable and designed to mimic the architecture of the native tendon.
The company is pursuing FDA clearance and intends to launch product in 2019.
This funding was led by 757 Angels and the Center for Innovative Technology, and builds upon the nearly $13.0MM previously raised by the company in a combination of an economic development loan ($0.15MM), state-based research grant ($0.8MM) and a DARPA grant to advance treatment of service members and veterans ($12.0MM).
Copy to clipboard 
